UCB Pharma announces partnership with Dynavax to develop and market products for the treatment of allergies
About UCB Pharma
UCB Pharma is one of Europe's leading pharmaceutical companies. It is active in all the world's major markets, specialising in the fields of allergy and respiratory diseases and in treatments for disorders of the central nervous system. Among products developed by UCB Pharma are XYZAL® (levocetirizine) a novel antihistamine, ZYRTEC® (cetirizine) the world's most widely used second generation antihistamine, and KEPPRA® (levetiracetam) a novel adjunctive therapy for the treatment of partial onset seizures associated with epilepsy. With over 6500 employees and operating in over 100 countries, UCB Pharma's global headquarters are in Brussels, Belgium. In 2003 it achieved a consolidated turnover of €1463 million.
Dynavax Technologies discovers, develops and intends to commercialise innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programmes are based on immunostimulatory sequences (ISS), which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Enquiries UCB Pharma
Head of Pharma Communication UCB Pharma
Tel: ++ 32 (0)2 559.93.42
Cell: ++ 32 (0) 499 56.57.80
Investor Relations Officer UCB Group
Tel: ++ 32 (0)2 559.92.64
Cell: ++ 32 (0) 4220.127.116.11.
Stay up-to-date on the latest news and information from UCB